Paula J Bates1, Elsa M Reyes-Reyes2, Mohammad T Malik3, Emily M Murphy4, Martin G O'Toole4, John O Trent3. 1. Department of Medicine, University of Louisville, USA; James Graham Brown Cancer Center, University of Louisville, USA. Electronic address: paula.bates@louisville.edu. 2. Department of Medicine, University of Arizona, USA. 3. Department of Medicine, University of Louisville, USA; James Graham Brown Cancer Center, University of Louisville, USA. 4. Department of Biomedical Engineering, University of Louisville, USA.
Abstract
BACKGROUND: AS1411 is a 26-mer G-rich DNA oligonucleotide that forms a variety of G-quadruplex structures. It was identified based on its cancer-selective antiproliferative activity and subsequently determined to be an aptamer to nucleolin, a multifunctional protein that preferentially binds quadruplex nucleic acids and which is present at high levels on the surface of cancer cells. AS1411 has exceptionally efficient cellular internalization compared to non-quadruplex DNA sequences. SCOPE OF REVIEW: Recent developments related to AS1411 will be examined, with a focus on its use for targeted delivery of therapeutic and imaging agents. MAJOR CONCLUSIONS: Numerous research groups have used AS1411 as a targeting agent to deliver nanoparticles, oligonucleotides, and small molecules into cancer cells. Studies in animal models have demonstrated that AS1411-linked materials can accumulate selectively in tumors following systemic administration. The mechanism underlying the cancer-targeting ability of AS1411 is not completely understood, but recent studies suggest a model that involves: (1) initial uptake by macropinocytosis, a form of endocytosis prevalent in cancer cells; (2) stimulation of macropinocytosis by a nucleolin-dependent mechanism resulting in further uptake; and (3) disruption of nucleolin-mediated trafficking and efflux leading to cargoes becoming trapped inside cancer cells. SIGNIFICANCE: Human trials have indicated that AS1411 is safe and can induce durable remissions in a few patients, but new strategies are needed to maximize its clinical impact. A better understanding of the mechanisms by which AS1411 targets and kills cancer cells may hasten the development of promising technologies using AS1411-linked nanoparticles or conjugates for cancer-targeted therapy and imaging. This article is part of a Special Issue entitled "G-quadruplex" Guest Editor: Dr. Concetta Giancola and Dr. Daniela Montesarchio.
BACKGROUND:AS1411 is a 26-mer G-rich DNA oligonucleotide that forms a variety of G-quadruplex structures. It was identified based on its cancer-selective antiproliferative activity and subsequently determined to be an aptamer to nucleolin, a multifunctional protein that preferentially binds quadruplex nucleic acids and which is present at high levels on the surface of cancer cells. AS1411 has exceptionally efficient cellular internalization compared to non-quadruplex DNA sequences. SCOPE OF REVIEW: Recent developments related to AS1411 will be examined, with a focus on its use for targeted delivery of therapeutic and imaging agents. MAJOR CONCLUSIONS: Numerous research groups have used AS1411 as a targeting agent to deliver nanoparticles, oligonucleotides, and small molecules into cancer cells. Studies in animal models have demonstrated that AS1411-linked materials can accumulate selectively in tumors following systemic administration. The mechanism underlying the cancer-targeting ability of AS1411 is not completely understood, but recent studies suggest a model that involves: (1) initial uptake by macropinocytosis, a form of endocytosis prevalent in cancer cells; (2) stimulation of macropinocytosis by a nucleolin-dependent mechanism resulting in further uptake; and (3) disruption of nucleolin-mediated trafficking and efflux leading to cargoes becoming trapped inside cancer cells. SIGNIFICANCE: Human trials have indicated that AS1411 is safe and can induce durable remissions in a few patients, but new strategies are needed to maximize its clinical impact. A better understanding of the mechanisms by which AS1411 targets and kills cancer cells may hasten the development of promising technologies using AS1411-linked nanoparticles or conjugates for cancer-targeted therapy and imaging. This article is part of a Special Issue entitled "G-quadruplex" Guest Editor: Dr. Concetta Giancola and Dr. Daniela Montesarchio.
Authors: Alexander S Minasyan; Srinivas Chakravarthy; Suchitra Vardelly; Mark Joseph; Evgueni E Nesterov; Irina V Nesterova Journal: Nanoscale Date: 2021-05-20 Impact factor: 7.790
Authors: Rebeca Carrión-Marchante; Valerio Frezza; Ana Salgado-Figueroa; M Isabel Pérez-Morgado; M Elena Martín; Víctor M González Journal: Pharmaceuticals (Basel) Date: 2021-05-17
Authors: Greta Garrido; Brett Schrand; Agata Levay; Ailem Rabasa; Anthony Ferrantella; Diane M Da Silva; Francesca D'Eramo; Koen A Marijt; Zhuoran Zhang; Deukwoo Kwon; Marcin Kortylewski; W Martin Kast; Vikas Dudeja; Thorbald van Hall; Eli Gilboa Journal: Cancer Immunol Res Date: 2020-04-15 Impact factor: 11.151